【ChiCTR-TTRCC-14004275】Effects of Acute Electroacupuncture Therapy Versus Transcutaneous Electrical Nerve Stimulation as Adjunctive Treatment for Sudden Sensorineural Hearing Loss: A Preliminary Study
ChiCTR-TTRCC-14004275
结束
/
/
/
2014-02-17
/
/
Sudden sensorineural hearing loss
Effects of Acute Electroacupuncture Therapy Versus Transcutaneous Electrical Nerve Stimulation as Adjunctive Treatment for Sudden Sensorineural Hearing Loss: A Preliminary Study
Effects of Acute Electroacupuncture Therapy Versus Transcutaneous Electrical Nerve Stimulation as Adjunctive Treatment for Sudden Sensorineural Hearing Loss: A Preliminary Study
To evaluate the effects of Electroacupuncture (EA) and compare its therapeutic efficacy to Trancutaneous electrical nerve stimulation(TENS) and conventional medical therapy in cases of ISSHL
随机交叉对照
Ⅱ期
Block randomization
/
National Research Council of Thailand (NRCT)
/
40
/
2012-06-26
2014-01-31
/
1. Male or female, age > 18 to 80 years and legal age of consent; 2. Has diagnosis of first episode of unilateral sudden sensorineural hearing loss; 3. Audiogram shows sensorineural hearing loss > 30 dB at least 1 frequency of the affected ear, and if the subject is older than 50 years old; the hearing threshold of the contralateral ear must be 10 dB less the affected ear.；
请登录查看1. History of head injury, loud noise exposure, use of ototoxic drugs, infections of middle ears, brain infections; 2. History of coagulation defects or receive anticoagulants/ antiplatelets; 3. History of epilepsy, seizure, stroke, cerebral ischemia, or has cardiac pacemakers; 4. Immunocompromised status, including a debilitated state or Malignancy; 5. Physical examination and laboratory results reveal following findings: Vesicles at pinna, ear canal, or tympanic membrane/ Perforated tympanic membrane/ Fluid in middle ear space/ CNS abnormality/ Abnormal VDRL or TPHA/ Significant prolonged PT, PTT, INR; 6. MRI or CT scan shows structural abnormality of brain and auditory nerve; 7. Lack of ability or willingness to give informed consent.；
请登录查看National Research Council of Thailand (NRCT)
/
National Research Council of Thailand (NRCT)的其他临床试验
Faculty of Medicine, Chiang Mai University, Thailand的其他临床试验
最新临床资讯
-
Nat Rev Clin Oncol｜AI赋能肿瘤临床试验：从流程优化到证据生成的全景透视
智药邦2026-08-12
-
康臣药业1类新药糖肾方“芪箭颗粒”获NMPA临床研究许可
康臣药业2026-08-12
-
璎黎药业2026-08-12
-
幂方健康基金2026-08-12
-
细胞与基因治疗领域2026-08-12
-
云南白药2026-08-12
-
细胞治疗前沿2026-08-12
-
广州达博生物制品有限公司2026-08-12
-
医药笔记2026-08-12
-
医药笔记2026-08-12
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29